Arena's February 2013 commercial launch of Belviq is around the corner!
Arena's (NASDAQ: ARNA) Belviq has become the first effective, safe and non-addictive obesity drug. According to a report from the Drug Enforcement Administration (DEA), Belviq should be classified as a Schedule IV drug, which means it has a low risk for abuse. The DEA's drug classification is required before a drug can be sold. This is great news for obese people who want easy access to Belviq. This is also great news for investors who want to see the commercial success of Belviq.
Arena's February 2013 commercial launch of Belviq is around the corner. Its partner Eisai is moving aggressively to prepare for its own role. The schedule IV classification allows physicians to prescribe Belviq to patients through local pharmacies for a three-month supply. Eisai argued that exceptional circumstances exist related to the obesity epidemic, and that a final order should be granted at the end of the notice period (Jan. 18). This final order will likely be granted, and Belviq will likely be available in local pharmacies in the first week of February 2013. Eisai already has a sales force in place which will market to physicians and educate them about this revolutionary weight management treatment.
Eisai has confirmed that Belviq is being loaded into drug store databases at major pharmacies in preparation for distribution. Major group and individual health insurance plans have already begun to cover Belviq, with Aetna and Blue Cross also planning coverage. Arena's CEO Jack Lief has hinted that Belviq will be priced under $4 a day for the two-pill daily dose. European approval is expected in early 2013. Arena has not yet finalized a partner in Europe as it will be in a better position to negotiate after this approval has been received.